Featured Research

from universities, journals, and other organizations

Oncolytic viruses mediating anti-tumor immunity in human cancer patients

Date:
May 19, 2010
Source:
University of Helsinki
Summary:
Researchers developing new cancer therapeutics based on the next generation oncolytic viruses have published initial results that demonstrate an anti-tumor immunity of oncolytic viruses -- published for the first time in humans -- and indicate the strong efficacy of the next generation viruses against solid tumor cancers.

Researchers from the University of Helsinki, and Oncos Therapeutics, a biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published initial results from their Advanced Therapy Access Program in Cancer Research. The therapy program is based on scientific research at the University of Helsinki and serves as the foundation for ongoing clinical development.

Related Articles


The results demonstrate an anti-tumor immunity of oncolytic viruses -- published for the first time in humans -- and indicate the strong efficacy of the next generation viruses against solid tumor cancers. As of today, 200 patients have been treated with oncolytic virus therapy in the company's Advanced Therapy Access Program.

"This is the first time it has been shown in humans that oncolytic viruses can be used for the induction of anti-tumor immunity. The GMCSF -armed oncolytic adenovirus can mediate anti-tumor immunologic responses by recruiting natural killer cells and by the induction of tumor-specific cytotoxic T-cells," explains research professor Akseli Hemminki, the CSO and co-founder of Oncos.

"Anti-tumor immunity plays a major role in the strong efficacy results. We are starting clinical trials with CGTG-102, which is further improved compared of the virus described in this publication," comments Pekka Simula, the CEO and co-founder of Oncos.

The Cancer Research article reports strong safety and efficacy results in patients with advanced cancer progressing after available chemotherapy options. Out of the 15 radiologically evaluable patients 2 had complete responses (13%), 5 patients had stable disease (33 %) and 1 had a partial response (6 %). Therefore, the clinical benefit rate was 47% according to the RECIST criteria. Responses were frequently seen in both injected and non-injected tumors. The safety profile was favorable with no grade 4-5 side effects realized.

"It has been impressive to see how powerful and consistent the oncolytic adenovirus platform is for directing the body's own immune system against tumor cells" says Dr. Vincenzo Cerullo, the scientist who led the project at the University of Helsinki Cancer Gene Therapy Group (CGTG).


Story Source:

The above story is based on materials provided by University of Helsinki. Note: Materials may be edited for content and length.


Journal Reference:

  1. Vincenzo Cerullo, Sari Pesonen, Iulia Diaconu, Sophie Escutenaire, Petteri T. Arstila, Matteo Ugolini, Petri Nokisalmi, Mari Raki, Leena Laasonen, Merja Särkioja, Maria Rajecki, Lotta Kangasniemi, Kilian Guse, Andreas Helminen, Laura Ahtiainen, Ari Ristimäki, Anne Räisänen-Sokolowski, Elina Haavisto, Minna Oksanen, Eerika Karli, Aila Karioja-Kallio, Sirkka-Liisa Holm, Mauri Kouri, Timo Joensuu, Anna Kanerva, and Akseli Hemminki. Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients. Cancer Research, 2010; DOI: 10.1158/0008-5472.CAN-09-3567

Cite This Page:

University of Helsinki. "Oncolytic viruses mediating anti-tumor immunity in human cancer patients." ScienceDaily. ScienceDaily, 19 May 2010. <www.sciencedaily.com/releases/2010/05/100518131714.htm>.
University of Helsinki. (2010, May 19). Oncolytic viruses mediating anti-tumor immunity in human cancer patients. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2010/05/100518131714.htm
University of Helsinki. "Oncolytic viruses mediating anti-tumor immunity in human cancer patients." ScienceDaily. www.sciencedaily.com/releases/2010/05/100518131714.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins